Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response

CONCLUSION: Overall, our results demonstrate that the detection and persistence of ctDNA at MT may have the potential to negatively predict response to neoadjuvant treatment and identify patients who will not achieve pCR or be classified with RCB II/III.PMID:34862246 | DOI:10.1158/1078-0432.CCR-21-3231
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research